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Annual risk of ONJ was the least important attribute. ConClusions: When making 
treatment decisions regarding choice of BTA for patients with bone metastases, the 
main treatment goals for Turkish physicians are reducing risk of renal impairment 
and delaying first SRE.
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objeCtives: To assess EQ-5D-5L validity in patients with acute stroke, in com-
parison to EQ-5D-3L, EQ VAS, modified Rankin Scale (mRS) and Barthel Index 
(BI). Methods: Cross-sectional study of 408 patients (51.5% males; mean age 69 
years), after median 8 days from stroke onset. We assessed: construct validity in 
terms of known-groups validity, convergent validity of EQ-5D-5L dimensions with 
other stroke outcome measures, and criterion-related validity in terms of concur-
rent validity, with mRS as a gold standard. Results: A total of 2.9% EQ-5D-5L and 
3.7% EQ-5D-3L questionnaires had at least one missing answer, indicating good 
feasibility of both instruments in patients with stroke. The proportion of patients 
reporting ‘no problems’ was 38.2% for BI, 6.1% for EQ-5D-3L, 5.6% for EQ-5D-5L, 
5.0% for mRS and 2.5% for EQ VAS. Results of the known-groups validity tests con-
firmed prior hypotheses: health state utilities were lower in females, patients with 
high mRS score, low BI or VAS score, patients with subarachnoid hemorrhage or 
intracerebral hemorrhage, and when proxy respondent was used. Convergence of 
EQ-5D-5L dimensions with mRS, BI and EQ VAS was improved or at least the same 
as EQ-5D-3L dimensions. For predicting outcome in patients with stroke, the sum 
of mRS related EQ-5D-5L dimensions (Mobility, Self-care, Usual activities), gave 1% 
of false positive and 0% of false negative results. ConClusions: Results support 
the validity of the EQ-5D-5L descriptive system as a generic measure assessed by 
self-report and proxy in patients with acute stroke, demonstrating some psycho-
metric advantages in comparison to EQ-5D-3L and substantially lower ceiling effect 
in comparison to Barthel Index.
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objeCtives: EQ-5D has been widely used to measure health status in a variety of 
conditions and the amount of evidence of its performance has increased over recent 
years. The aim of this study was to consolidate this evidence by reviewing papers 
reporting systematic reviews of the psychometric properties (validity and reliability) 
and/or responsiveness of EQ-5D. Methods: Medline and Embase were searched 
for systematic reviews of the performance of EQ-5D. Supplementary searches were 
carried out in Cochrane Library, Web of Science, reference lists of included studies, 
the EuroQol database and hand searching of EuroQol Scientific Plenary Proceedings. 
In addition the website of the Oxford Patient Reported Outcome Measures (PROMs) 
Group was searched for reports. Data were extracted using a template designed 
specifically for the study. Results: 25 reviews were identified in this study and a 
further 18 were identified from the Oxford PROMs group website. The majority of 
studies focussed on adults. Overall there was evidence of good to fair performance 
of EQ-5D in depression, diabetes (type 2), rheumatoid arthritis, skin conditions, can-
cer, cardiovascular disease, asthma, personality disorder and urinary incontinence. 
Evidence was mixed in COPD, dementia, schizophrenia and vision disorders, and 
poor for hearing disorders. The was little evidence for liver transplantation, venous 
leg ulcers, haemophilia, bipolar disorder and low back pain; although limited, the 
evidence showed positive results for liver transplantation, haemophilia and leg 
ulcers. No evidence was identified for, among others, skin cancer and systemic lupus 
erythematous. ConClusions: This study has provided a comprehensive overview 
of the evidence of the performance of EQ-5D. Most evidence suggests good psycho-
metric properties of EQ-5D; however there are particular concerns about its ability 
to capture the impact of dementia, schizophrenia, visual impairment and hearing 
disorders. Further research is encouraged in conditions where data or reviews of 
psychometric properties of EQ-5D are lacking.
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objeCtives: To investigate health-related quality of life (HRQoL) in Italian 
patients with moderate and severe Crohn’s disease (CD) (Harvey Bradshaw 
Index> 8). Methods: EuroQoL 5-dimension 3-level (EQ-5D-3L) questionnaire 
and visual analogue scale (VAS) were administered to 540 consecutive patients 
with moderate and severe CD who referred to a convenience sample of 38 Italian 
inflammatory bowel disease centres (21 teaching-hospitals; 4 research hospitals; 
8 self-governing hospitals; 3 Local Health Authority hospitals; 2 private hospi-
tals) participating in the ongoing Survey on Quality Of Life in Crohn’s Patients (SOLE) 
objeCtives: Currently no measure can identify, with a high degree of positive pre-
dictive power, suicidal behavior. Because suicide occurs at a low base-rate, studies 
of instruments designed to predict this outcome often lack an adequate sample 
size to prove the tool’s predictive ability. Our aim is to identify an assessment with 
the most promise of predicting suicidal behavior in veteran or military patients and 
present options to overcome previous research hurdles. Methods: Two systematic 
reviews, one performed for the US Department of Veterans [1], and the other as 
part of NICE guidance development [2] provided the background for our analy-
sis. These summaries were reviewed to identify the most predictive assessments 
yet developed. Sensitivity, specificity, positive and negative predictive power were 
tabulated for all reported instruments. Study limitations were recorded along with 
these results. Results: One instrument showed promise of meeting the objec-
tive. The Affective States Questionnaire (ASQ) was able to predict suicide within 3 
months with a sensitivity of 60%, specificity of 74% and positive predictive power 
of 32% [3]. The study that produced those results was performed on an inpatient 
and outpatient veteran population. However, the sample was small with only 283 
patients and the risk of bias was unclear. A larger study may provide the needed 
evidence to make the Affective States Questionnaire a useful screening tool. We 
propose the Affective States Questionnaire be transferred to electronic administra-
tion and provided as part of routine admissions at VA facilities. Deploying the tool 
electronically could provide the large sample sizes required to detect effects on this 
low base-rate outcome. ConClusions: The Affective States Questionnaire shows 
promise of becoming an appropriate screening tool for suicide in a military popu-
lation. Electronic capture may allow for large scale deployment, therefore gaining 
sufficient sample to determine applicability as a screening tool.
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objeCtives: To evaluate psychometric properties of the revised Self-Injection 
Assessment Questionnaire in rheumatoid arthritis patients (pts) receiving certoli-
zumab pegol. Methods: In the study (NCT00674362), pts with low to moderate 
rheumatoid arthritis (RA) received certolizumab pegol (CZP; 400mg at Weeks [Wks] 
0, 2, 4, then 200mg every other wk). In the open-label extension (OLE; NCT00843778), 
pts could self-administer CZP using a pre-filled syringe. Pts in OLE completed the 
revised Self-Injection Assessment Questionnaire (SIAQv2.0
©) at Wks 0, 2, 4, 6, 8, 10, 12. 
Domain scores were calculated per authors’ recommendations, and internal consist-
ency was assessed using the Cronbach’s alpha statistics. Floor and ceiling effects 
were reported as % pts with the worst/best domain score. Construct validity was 
assessed by confirmatory factor analysis fitting the current conceptual framework 
of the questionnaire and by calculating the Bentler’s Comparative Fit Index (CFI) 
and the root mean square error of approximation (RMSEA). Results: 86 pts (mean 
age: 50.8 years; disease duration: 4.6 years) entered the OLE and completed the SIAQ 
at least once. At first self-injection visit, DAS28 (ESR) was 4.0 and HAQ-DI 0.9. The 
internal consistency of all domains was > 0.8 at any visit. Floor effect was < 5% at any 
visit; ceiling effect was ≤ 13% for Self-Confidence, Ease of Use (EU) and Satisfaction 
domains, but reached 40% for Feeling and Injection-Site Reactions domains. The 
ceiling effect of the EU domain was lower (10%) than the original validation (22%). 
The conceptual framework structure was supported by the confirmatory factor 
analysis with CFI values of 0.75–0.86 and RMSEA values of 0.10–0.13, which, given 
the limited sample size, would indicate reasonable goodness of fit. ConClusions: 
Modifications brought to the SIAQv2.0
© appeared to remediate the acquiescence 
bias issue that was noted during the validation of SIAQv1. The appropriateness 
of the internal consistency reliability and construct validity of the SIAQv2.0
© were 
confirmed.
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objeCtives: To evaluate Turkish physicians’ preferences when selecting 
between the different bone-targeted agents (BTAs) available for preventing skel-
etal-related events (SREs) in patients with bone metastases from advanced solid 
tumors. Methods: Physicians from several centres, currently treating patients with 
bone metastases from solid tumours were recruited by phone or personal invitation 
and then engaged in a face-to-face interview where they completed a web-ena-
bled discrete-choice experiment survey. Each survey included 10 choices between 
pairs of hypothetical treatment profiles for the two putative patient profiles. The 
hypothetical treatment profiles included five attributes within a pre-defined range 
(based on prescribing information): time until first SRE (10, 18 and 28 months); time 
until worsening of pain (3, 6 and 10 months); annual risk of osteonecrosis of the 
jaw (ONJ; 0, 1 and 5%); annual risk of renal impairment (0,4 and 10%); and mode 
of administration (oral tablet, subcutaneous injection, 15-minute or 120-minute 
intravenous infusion). Choice questions were based on an experimental design 
with known statistical properties. A main-effects random parameters logit model 
was estimated. Results: A total of 105 physicians agreed to participate in the 
face-to-face interview and accessed the online survey. Of these, 104 physicians 
were eligible and consented to participate and 99 were included in the analysis. 
Estimated preference weights for all applicable attributes were consistent with the 
natural ordering of the categories. Risk of renal impairment and months until first 
SRE were the most important attributes influencing physicians’ decisions, with 
better clinical outcomes preferred to worse outcomes. Preventing pain progres-
sion was the third most important attribute followed by mode of administration. 
